Renal Cancer - Results from #680

Management of renal cell carcinoma: promising biomarkers and the challenges to reach the clinic. October 26, 2023

Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma. October 25, 2023

Family History and Risk of Renal Cell Carcinoma: A National Multi-Register Case-Control Study. October 24, 2023

Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101. October 24, 2023

Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid Cancer Treated With VEGFR TKIs. October 23, 2023

Outcomes of Patients With Advanced Renal Cell Carcinoma With Non-Clear Cell Histology Treated With Systemic Therapy. October 23, 2023

Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial. October 20, 2023

Advances in non-clear cell renal cell carcinoma management: From heterogeneous biology to treatment options. October 20, 2023

Recent Advances in Single-Cell RNA-Sequencing of Primary and Metastatic Clear Cell Renal Cell Carcinoma. October 19, 2023

A comprehensive prognostic and immunological analysis of telomere-related lncRNAs in kidney renal clear cell carcinoma. October 19, 2023

A Rare Presentation of Aggressive Renal Cell Carcinoma and the Utility of Early Molecular Testing in Rapidly Progressing Malignancies: A Case Report. October 18, 2023

Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial. October 18, 2023

Artificial Intelligence in Surgical Training for Kidney Cancer: A Systematic Review of the Literature. October 17, 2023

Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma. October 17, 2023

18F-fluoro-2-deoxy-2-d-glucose PET-CT (FDG PET-CT) in staging of high-risk renal and urothelial bladder cancers (COPPER-T) trial protocol. October 16, 2023

2018 Leibovich prognostic model for renal cell carcinoma: Performance in a large population with special consideration of Black race. October 16, 2023

Adverse Events of Cabozantinib Plus Nivolumab Versus Ipilimumab Plus Nivolumab. October 13, 2023

An Updated Systematic Review and Meta-Analysis on the Technical, Oncologic, and Safety Outcomes of Microwave Ablation in Patients with Renal Cell Carcinoma. October 13, 2023

Prognostic Significance of Pathologic Lymph Node Invasion in Metastatic Renal Cell Carcinoma in the Immunotherapy Era. October 12, 2023

Renal cell carcinoma outcomes in end-stage renal disease: A 40-year study from two Japanese institutions. October 12, 2023

Page 35 of 456